BRIEF-FDA Review Of Citizen Petition Offers A Fresh Look At NurOwn®'S Evidence Of Treatment Effectiveness

Reuters07-08

July 8 (Reuters) - Brainstorm Cell Therapeutics Inc BCLI.O:

FDA REVIEW OF CITIZEN PETITION OFFERS A FRESH LOOK AT NUROWN®'S EVIDENCE OF TREATMENT EFFECTIVENESS
BRAINSTORM CELL THERAPEUTICS INC - TO CONTINUE PHASE 3B TRIAL FOR ALS

Source text: ID:nPn1qRJLpa

Further company coverage: BCLI.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2549932541?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-08 19:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549932541","market":"us","top_or_hot":-1,"title":"BRIEF-FDA Review Of Citizen Petition Offers A Fresh Look At NurOwn®'S Evidence Of Treatment Effectiveness","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-FDA Review Of Citizen Petition Offers A Fresh Look At NurOwn®'S Evidence Of Treatment Effectiveness</title></head><body><p><span>July 8 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/BCLI\">Brainstorm Cell</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>BCLI.O</span>:</p><ul><li><p>FDA REVIEW OF CITIZEN PETITION OFFERS A FRESH LOOK AT NUROWN®'S EVIDENCE OF TREATMENT EFFECTIVENESS</p></li><li><p>BRAINSTORM CELL THERAPEUTICS INC - TO CONTINUE PHASE 3B TRIAL FOR ALS</p></li></ul><p>Source text: <span>ID:nPn1qRJLpa</span></p><p>Further company coverage: <span>BCLI.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-FDA Review Of Citizen Petition Offers A Fresh Look At NurOwn®'S Evidence Of Treatment Effectiveness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-FDA Review Of Citizen Petition Offers A Fresh Look At NurOwn®'S Evidence Of Treatment Effectiveness\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-08 19:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-FDA Review Of Citizen Petition Offers A Fresh Look At NurOwn®'S Evidence Of Treatment Effectiveness</title></head><body><p><span>July 8 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/BCLI\">Brainstorm Cell</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>BCLI.O</span>:</p><ul><li><p>FDA REVIEW OF CITIZEN PETITION OFFERS A FRESH LOOK AT NUROWN®'S EVIDENCE OF TREATMENT EFFECTIVENESS</p></li><li><p>BRAINSTORM CELL THERAPEUTICS INC - TO CONTINUE PHASE 3B TRIAL FOR ALS</p></li></ul><p>Source text: <span>ID:nPn1qRJLpa</span></p><p>Further company coverage: <span>BCLI.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nTUABC9S0H:1","article_id":"2549932541","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549932541","pubTimestamp":1751974377,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-FDA Review Of Citizen Petition Offers A Fresh Look At NurOwn'S Evidence Of Treatment EffectivenessJuly 8 (Reuters) - Brainstorm Cell Therapeutics Inc BCLI.O:FDA REVIEW OF CITIZEN PETITION OFFERS","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BCLI":"BrainStorm Cell Therapeutics Inc."},"translate_title":"简介-FDA对公民请愿书的审查为NurOwn提供了新的视角®治疗有效性的证据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCLI":0.9},"content_text":"BRIEF-FDA Review Of Citizen Petition Offers A Fresh Look At NurOwn®'S Evidence Of Treatment EffectivenessJuly 8 (Reuters) - Brainstorm Cell Therapeutics Inc BCLI.O:FDA REVIEW OF CITIZEN PETITION OFFERS A FRESH LOOK AT NUROWN®'S EVIDENCE OF TREATMENT EFFECTIVENESSBRAINSTORM CELL THERAPEUTICS INC - TO CONTINUE PHASE 3B TRIAL FOR ALSSource text: ID:nPn1qRJLpaFurther company coverage: BCLI.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2549932541","isCrawlerRequest":true}